BiOptix Announces Support of the 8th Annual PEGS Summit
BOULDER, Colo., April 30, 2012 /PRNewswire/ — BiOptix today announced participation in the 8th Annual PEGS: Protein Engineering Summit, to be held in Boston April 30 – May 4, 2012. Supporting PEGS allows BiOptix to showcase a growing family of Enhanced Surface Plasmon Resonance Instrumentation, highlighting the BiOptix 104sa and the forthcoming BiOptix 404pi.
“Participation in PEGS is a valuable opportunity for us to connect to our core customer,” noted Ken Wilczek, Vice President of Sales and Marketing for BiOptix. Mr. Wilczek continued “With the 104sa and the upcoming 404pi, BiOptix is positioned for success in the market with an Enhanced SPR technology that allows researchers to perform protein-protein kinetics as well as protein-small molecule analysis in a high-throughput manner with high sensitivity.”
Specifically, BiOptix instrumentation is capable of performing the following biological applications:
- Protein-small molecule interactions
- Protein-protein kinetics
- Antibody affinities & epitope mapping
- Oligosaccharide characterization
- Nucleic acid (DNA-DNA or DNA-RNA) hybridization
- Biomolecule concentration measurements
Surface Plasmon Resonance is an advanced and highly sensitive optical technology that can measure refractive index changes on a sensor chip’s gold surface due to a change in mass that occurs during a binding event. This change can be used to monitor biological interactions such as the concentration of target molecules, kinetic rates and affinity constants. BiOptix has developed and patented a novel ultra-sensitive detection platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional SPR, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry.
“The market for Surface Plasmon Resonance instrumentation continues to grow exponentially,” noted Rick Whitcomb, President and CEO for BiOptix. “BiOptix has a unique and winning value proposition in the market in that we offer the first commercial instrument to employ a patented phase-based and Enhanced SPR technology.”
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction–with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
SOURCE BiOptix Diagnostics Corporation